<h2>EU News</h2>
<h3>New Head of EMA</h3>
<p>Emer Cooke is the new Executive Director of the European Medicines Agency. Emer took over as head of the EMA on November 16, 2020. Emer said her priorities for the Agency would be the access and affordability of medicines.</p>
<h3>Clinical Trial Regulation Implementation</h3>
<p>The Clinical Trials (CT) Regulation 536/2014 published on May 28, 2014 has yet to be implemented as it requires a new portal, the Clinical Trials Information System (CTIS), to be operational for new processes to be functional. At its Management Board meeting on June 11, the EMA proposed December 2021 as the go-live date for the CTIS and CT regulation implementation.</p>
<p>Once the CTIS goes live, a three-year transition period to the new system will commence. In the first year of this transition, sponsors of clinical trials will be allowed to submit applications using either the existing EudraCT system or the CTIS. In years two and three, new CTA applications must be done via the CTIS. Trials authorized via EudraCT can continue but must be transferred to the CTIS by end of the three-year transition period.</p>
<h3>Nitrosamine Contamination</h3>
<p>On June 25, 2020, a Committee for Medicinal Products for Human Use (CHMP) Assessment Report recommended extending the requirement to conduct a risk assessment to consider the possibility of the presence of nitrosamine contamination to biological medicinal products. This requirement applies to both new marketing authorization applications and all existing products.</p>
<p>In August 2020, the EMA provided a deadline for the completion of the risk assessments and report of the outcome for biological products and, at the same time, further extended the deadline for products with chemically produced APIs to:</p>
<ul><li>March 31, 2021 for chemical medicines</li><li>July 1, 2021 for biological medicines</li></ul>
<p>In December 2020, the European Pharmacopoeia (Ph. Eur.) Commission adopted a new general chapter on the analysis of N-nitrosamine impurities in active substances (2.5.42, previously listed as 2.4.36).</p>
<h3>Water Quality Guideline</h3>
<p>In July 2020, the EMA issued an update to the &ldquo;Guideline on the quality of water for pharmaceutical use,&rdquo; which becomes effective on February 1, 2021. This revision is the first in 18 years.</p>
<p>The guidance lists the four types of water that can be used for manufacturing drug substances and finished drug products:</p>
<ul><li>Water for injection, which is mainly used for sterile products</li><li>Purified water, which is used for non-sterile products and certain active substances</li><li>Potable water, which can be used for manufacturing active substances and the early stages of cleaning equipment</li><li>Water for the preparation of extracts, which is a new category for herbal products</li></ul>
<p>This new guidance permits the use of potable water for producing the fermentation media and cell culture media in making active substances for biological products, whereas the preceding draft called for using higher-grade purified water for producing such media.</p>
<h2>Brexit</h2>
<p>On December 24, 2020, the EU and UK finally agreed to a trade deal. Annex TBT-2 of this trade deal contains the agreed provisions for medicinal products. The agreement applies to the following medicinal products for human and veterinary use:</p>
<ul><li>Marketed medicinal products for human or veterinary use, including marketed biological and immunological products for human and veterinary use</li><li>Advanced therapy medicinal products</li><li>Active pharmaceutical ingredients for human or veterinary use</li><li>Investigational medicinal products</li></ul>
<p>The agreement includes the following:</p>
<ul><li>Mutual recognition of GMP inspections. Unfortunately, this agreement is not a mutual recognition agreement (MRA) and does not include removing the requirement for re-testing of product made in the UK on importation into the EU, and vice versa. For political reasons this requirement may not be removed for several years, if ever.</li></ul>
<ul><li>Regulatory cooperation</li></ul>
<p>Notable absences from the trade agreement include any mention of herbal medicinal products or medical devices. Also absent is any arrangement for a two-way alert system or pharmacovigilance information sharing.</p>
<p>From January 1, 2021, the MHRA has published a library of new guidance that applied as the transition period came to an end. This guidance covers the following areas:</p>
<ul><li>Clinical trials</li><li>Devices</li><li>Importing and exporting</li><li>IT systems</li><li>Legislation</li><li>Licensing</li><li>Pharmacovigilance</li><li>Pediatrics</li></ul>
<h2>ICH News</h2>
<p>The 2020 ICH biannual meetings, scheduled to be held in Canada in May and Greece in November, were both converted to virtual meetings due to the COVID-19 pandemic and the resulting global travel restrictions. The next ICH meeting is scheduled for June 2021 in South Korea.</p>
<p>In October 2020, the assembly endorsed the concept paper for the revision of Q9, Quality Risk Management. The concept paper for Q9 (R1) lists four areas for improvement with the current application of QRM:</p>
<ul><li>High levels of subjectivity in risk assessments and in QRM outputs</li><li>Product availability risks</li><li>Lack of understanding as to what constitutes formality in QRM work</li><li>Lack of clarity on risk-based decision-making</li></ul>

regulation

European Pharmacopoeia

Emer Cooke

International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Pharma Regulatory

executive director

EudraCT

EU News
New Head of EMA
Emer Cooke is the new Executive Director of the European Medicines Agency. Emer took over as head of the EMA on November 16, 2020. Emer said her priorities for the Agency would be the access and affordability of medicines.
Clinical Trial Regulation Implementation
The Clinical Trials (CT) Regulation 536/2014 published on May

EU, ICH and Brexit Pharma Regulatory Update - July 2020 to January 2021

DFS Operator - 12hr Night Shift:
Today, Lonza is a global leader in life sciences operating across three continents. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising ideas that help businesses to help people. In exchange, we let our people own their ca

Technician, Diagnostics

Internal controls serve as a fundamental pillar within corporate governance, risk management, and regulatory compliance, ensuring that organizations operate efficiently, ethically, and in line with established laws and regulations. These controls—comprising policies, procedures, and mechanisms—are designed to safeguard assets, ensure the accuracy o

How to Mitigate Limitations of Internal Controls?

Join our webinar to see how MODSIM transforms industrial equipment design by reducing costs and improving collaboration through integrated modeling and simulation.
Industrial equipment manufacturers face significant challenges, particularly in reducing project costs during the bidding phase. Users often must work with pre-defined CAD solutions, whi

MODSIM for Designers in the IE Industry

Ideagen Document Review, formerly known as Ideagen PleaseReview, has partnered with Veeva to offer customers the ability to collaborate on large documents with very high-volume teams—all from within Vault.
Introducing Veeva Vault + Ideagen Document Review
Ideagen Document Review is a real-time document review, co-authoring and redaction software ta

How Ideagen Document Review supports document reviews within Veeva Vault

What would it be like to reduce the audit trail review (ATR) burden in laboratories and manufacturing spaces all while satisfying inspector expectations? With more than 100 external inspections of Eli Lilly and Company’s commercial manufacturing sites conducted in the two years since the company published a novel and enhanced ATR assessment process

A Novel, Enhanced, and Sustainable Approach to Audit Trail Review

Next phase builds on 34+ years of serving the needs of US patients and healthcare providers
Columbus, OH /PRNewswire/ - In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities

Hikma Pharmaceuticals USA Announces $1B Of New US Investment To Further Expand Its Domestic Manufacturing And Development Of Essential Generic Medicines

With at-home testing becoming normalized after the pandemic, manufacturers should break down the entire process—from receiving the kit to obtaining the results—and consider how packaging can simplify the process.
Follow this podcast on your favorite streaming platform - links can be found by clicking here.
Learn More

Through the Line: At-home Test Kits

Friday, July 04, 2025
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) has granted marketing authorisation in the European Union (EU) for Vevzuo® and Evfraxy® biosimilars of Denosumab.
Vevzuo® is authorised for the prevention of bone complicati

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

Product name
METAGENICS MAGACTIVE MUSCLE POWDER RASPBERRY
ARTG Date
Registration Type
Medicine
Therapeutic good type
Medicine
Sponsor
Metagenics (Aust) Pty Ltd
Ingredients
acetyl levocarnitine hydrochloride
ascorbic acid
calcium hydrogen phosphate dihydrate
chromium nicotinate
glutamine
magnesium glycinate
magnesium glycinate dihydrate
mecobalamin

METAGENICS MAGACTIVE MUSCLE POWDER RASPBERRY

EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), have issued recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins.
These medicines are currently the only available treatment for the prevention of RhD immunisation during pregn

Strengthening supply chain of anti-D immunoglobulins

Aging of the global population and the rise of chronic diseases, particularly diabetes, have contributed to an increase in the occurrence of eye diseases, such as glaucoma, keratitis, age-related macular degeneration (AMD), dry eye disorder (DED), and diabetic retinopathy (DR). Pharmaceutical companies have responded with growing investment in the

Advanced Solutions for Sustained Delivery of Ocular Therapies

Racemization is the process of converting an optically active compound into a racemic (optically inactive) mixture — comprising equal parts of two enantiomers — typically through the application of heat or a chemical reaction. Because many chemical reactions are stereoselective, only one enantiomer often leads to the desired biological effect, whil

Elevating Purity Levels: Racemizing Pharmaceutical Products In Advanced Flow Microreactors

Friday, July 04, 2025
Biopharmaceutical high-tech company InnoCare Pharma announced today that its independently developed novel ADC innovative drug ICP-B794 targeting B7-H3 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for clinical research.
ICP-B794 is a humanized anti-B7-H3 monoc

InnoCare Pharma's new ADC innovative drug ICP-B794 was approved for clinical trials

ARTG ID 496975
ARTG Name
METAGENICS MAGACTIVE MUSCLE TABLET
Product name
METAGENICS MAGACTIVE MUSCLE TABLET
ARTG Date
Registration Type
Medicine
Therapeutic good type
Medicine
Sponsor
Metagenics (Aust) Pty Ltd
Ingredients
chromic chloride hexahydrate
magnesium amino acid chelate
magnesium glycinate
magnesium glycinate dihydrate
pyridoxal 5-phosphat

METAGENICS MAGACTIVE MUSCLE TABLET

In 2025, the MHRA issued a change to the regulations for licensure of medicines employing cell and gene therapy technology.1 This change is particularly relevant to those treatments that require a significant manufacturing activity outside the traditional manufacturing plant, especially at the bedside of patients. The building blocks of these autol

7 New MHRA Guidances To Help You With Decentralized Manufacturing For Cell And Gene Therapies

Process validation1,2 is often considered by management to be a costly regulatory formality — a necessary checkbox with little perceived business value. This mindset has caused some organizations to minimize validation investments, delegate the responsibility to underqualified personnel, or skip essential steps for short-term savings.
However, this

Process Validation: Optimizing Operational Excellence In Pharma And Medical Devices

Thursday, July 03, 2025
Neurizon Therapeutics Limited a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmac

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

ARTG ID 496605
ARTG Name
Skin + Digestion
Product name
Skin + Digestion
ARTG Date
Registration Type
Medicine
Therapeutic good type
Medicine
Sponsor
JSHealth Vitamins Pty Ltd
Ingredients
ascorbic acid
Aloe vera
Arctium lappa
calcium pantothenate
colloidal anhydrous silica
Calendula officinalis
Curcuma longa
d-alpha-tocopheryl acetate
glutamine
Genti

Skin + Digestion

While it has been June gloom in California, when the gray marine layer forms over the Pacific Ocean and it stays cloudy on the beaches (especially in the mornings) for most of the month, it looks like the coast was clear in Bethesda, Maryland as the OGD unofficially issued 66 full-approval actions and 20 tentative-approval actions for a total of 86

Unofficial June 2025 ANDA Approvals

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product

June 2025 — CDMO Opportunities And Threats Report

Thursday, July 03, 2025
Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) is a clinical-stage cell therapy company headquartered in Hsinchu, Taiwan, advancing mesenchymal stem cell (MSCs) therapies. Leveraging its patented technologies, the company's platform provides safer and potent therapies with solid evidence, which there are four ste

Gwo Xi Stem Cell Company Powers Local Regenerative Medicine, Partners with Japan to Open a New Era

ARTG ID 496525
ARTG Name
INNER HEALTH HAYFEVER RELIEF PROBIOTIC
Product name
INNER HEALTH HAYFEVER RELIEF PROBIOTIC
ARTG Date
Registration Type
Medicine
Therapeutic good type
Medicine
Sponsor
Metagenics (Aust) Pty Ltd
Ingredients
Lactobacillus paracasei
Licence category
LI
Licence status
A
Summary
Download PDF

INNER HEALTH HAYFEVER RELIEF PROBIOTIC

Thursday, July 03, 2025
Dizal has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ZEGFROVY® (sunvozertinib) to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations.
EGFR exon 20 insertion mutations are a rare and complex form of

Dizal's ZEGFROVY® Receives FDA Accelerated Approval as First Oral Therapy for EGFR Exon20ins NSCLC

The process of commissioning, qualification, and validation (CQV) sits on the critical path between a promising production line and commercial supply. Yet even in 2025, many life sciences companies still rely on binders of paper, wet‑ink signatures, and spreadsheets to prove that every asset performs as intended. Those manual steps can stretch sche

From Weeks to Minutes: How Intelligent Automation Transforms CQV Workflows

FDA announced on June 27, 2025, that Sandoz, Inc. is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial after customers complained that four penicillin G potassium for injection, USP, 20 million units labeled vials were incorrectly included in a carton of Cefazolin for Injection vials (1). While the company states it has